Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CDX-3379 |
Synonyms | |
Therapy Description |
CDX-3379 (KTN3379) is a monoclonal antibody that targets ERBB3 (HER3) and prevents ligand binding and downstream signaling, potentially leads to inhibition of tumor cell growth (PMID: 31308059). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-3379 | CDX3379|MEDI3379|KTN3379 | HER3 (ERBB3) Antibody 23 | CDX-3379 (KTN3379) is a monoclonal antibody that targets ERBB3 (HER3) and prevents ligand binding and downstream signaling, potentially leads to inhibition of tumor cell growth (PMID: 31308059). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 positive | melanoma | sensitive | CDX-3379 | Preclinical | Actionable | In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation and ERBB3 (HER3)-AKT signaling in a human melanoma cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266). | 26880266 |
ERBB3 positive | head and neck squamous cell carcinoma | predicted - sensitive | CDX-3379 | Phase I | Actionable | In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731). | 31308059 |
ERBB3 positive | breast cancer | sensitive | CDX-3379 | Preclinical | Actionable | In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation of a human breast cancer cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266). | 26880266 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02473731 | Phase I | CDX-3379 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Completed | USA | 0 |